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Abstract
Centuries of scientific advances and developments in biomedical sciences have brought us a long way to under-
standing and managing disease processes, by reducing them to simplified cause-effect models. For most of the
infectious diseases known today, we have the methods and technology to identify the causative agent, understand
the mechanism by which pathology is induced and develop the treatment (drugs, vaccines, medical or surgical
procedures) to cure, manage or control.
Disease, however, occurs within a context of lives fraught with complexity. For any given infectious disease, who
gets it, when, why, the duration, the severity, the outcome, the sequelae, are bound by a complex interplay of fac-
tors related as much to the individual as it is to the physical, social, cultural, political and economic environments.
Furthermore each of these factors is in a dynamic state of change, evolving over time as they interact with each
other. Simple solutions to infectious diseases are therefore rarely sustainable solutions. Sustainability would require
the development of interdisciplinary sciences that allow us to acknowledge, understand and address these com-
plexities as they occur, rather than rely solely on a form of science based on reducing the management of disease
to simple paradigms.
In this review we examine the current global health responses to the ‘neglected’ tropical diseases, which have
been prioritised on the basis of an acknowledgment of the complexity of the poverty-disease cycle. However
research and interventions for neglected tropical diseases, largely neglect the social and ecological contextual, fac-
tors that make these diseases persist in the target populations, continuing instead to focus on the simple biomedi-
cal interventions. We highlight the gaps in the approaches and explore the potential of enhanced interdisciplinary
work in the development of long term solutions to disease control.
Introduction - The neglected tropical diseases
The Millennium Declaration provided a catalyst around
which the global community, particularly world leaders,
could refocus efforts and recognise responsibilities
towards the most vulnerable and least served in society.
It forced the world’s attention onto those sections of the
community left behind by the rapid progress in technol-
ogy, highlighting the downward spiral of those unable to
access the advantages of development.
The operationalisation of the Millennium Declaration
through the Millennium Development Goals (MDGs)
attempted to target the various factors that cause and
sustain poverty and its consequences. These have had a
significant impact on public health across a number of
areas. In the area of communicable diseases there has
been significant, increased activity and progress across a
number of diseases that affect the poor. HIV/AIDS,
malaria and tuberculosis (the “big three”) are given
priority in MDG 6 - collectively they account for over 5
million deaths annually [1]. Several partnerships and
initiatives have been created with more ‘ring fenced’
resources than have ever been available to global health
efforts [2]. The funds support programs, drug and vac-
cine developments and the scale up of various interven-
tions. The increase in global health activity across these
three diseases is reflected in increased public awareness,
access to treatment, funding for research and
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development and ongoing monitoring and evaluation to
ensure accountability and the achievement of targets.
Others have argued, however, that the focus on the
big three has been at the cost of other health priorities
that also adversely affect vulnerable, disenfranchised and
neglected populations [3,4]. Diseases such as schistoso-
miasis, soil transmitted helminths, lymphatic filariasis,
onchocercias, dracunculiasis, buruli ulcers, leprosy (to
name a few) have a significant impact on the poor.
Described as neglected tropical diseases (NTDs), these
conditions fall within a category of infectious diseases
that predominantly affect over a billion of the world’s
poorest people, are disabling, disfiguring and stigmatiz-
ing. They are ‘neglected’ because they are the diseases of
“forgotten people” with high endemicity in rural and
impoverished urban areas of low income countries and
conflict and post conflict regions; the consequences are
impaired childhood growth and intellectual develop-
ment, low worker productivity, high maternal morbidity.
These are diseases that both cause and are the result of
poverty. Furthermore, there is a shortage of safe and
effective treatments because these diseases present low
priority markets for pharmaceutical companies [6].
Over the last five years, the WHO and the Centers for
Diseases Control and Prevention (CDC) in Atlanta have
identified a group of these diseases that present “targets
of opportunity” based on the potential for control and
possibly elimination at a low cost [7,8]. There has there-
fore been a significant lobby to develop a separate initia-
tive to tackle NTDs. The lobby has had some success.
Funding for NTDs has increased, as have commitments
from the G8 countries and global health philanthropists.
New funds from USAID for instance have been released
specifically for NTD programs. Furthermore a number
of pharmaceutical companies have donated products or
are supporting public private partnerships, under their
programs for corporate social responsibility, towards
research and development for NTD control. Several glo-
bal health initiative have also been established to address
NTDs including: a dedicated World Health Organization
department; a Global Network for NTDs, Research Part-
nerships and Research Initiatives and a dedicated peer
reviewed academic journal. Given the current success of
the NTDs in achieving the status as one of the 21st cen-
tury’s “gang of four” [9] [page e102], the issue of
‘neglect’, particularly by drug research and development,
becomes difficult to justify.
Current efforts to address neglected tropical
diseases
The WHO NTDs program published a global plan to
2015 with details on the various strategic areas [10-12]
and the web sites of various partnerships and alliances
also provide updates on their activities and funded
programs. Most recently, The Lancet journal published a
series in early 2010 on NTD programs (see for instance
[13-16].
Although varied the range of programs share at least
one of three goals; control, elimination or eradication.
The strategies for achieving these include intensified
efforts on single disease vertical control programs or co-
implementation across multiple disease programs where
co-morbidities occur [17]. The main intervention is pre-
ventive chemotherapy delivered through mass drug
administration of ‘rapid impact packages [9,3].’ The
African Programme for Onchocerciasis Control (APOC),
with donations from Merck, for instance has delivered
Mectizan(tm) for onchocerciasis control since the mid
1990 s. Similar programs deliver Albendazole (donated
by GlaxoSmithKline) for lymphatic filariasis. The distri-
bution of additional preventive chemotherapies for de-
worming as well as treatment of whole communities for
relevant diseases in order to interrupt transmission
cycles [18-21] should therefore not require major extra
costs. There are also intensified efforts towards case
management to identify and treat people with diseases
and a renewed effort for surveillance, mapping of co-
occurrence of infections and vector control.
The increase in resources for NTDs, has also seen an
increase in advocacy for vaccine development described
as the anti-poverty vaccine [22,23]. Hotez et al argue
that vaccines against the various stages of helminth
development and administered at the same time as mass
drug administration would be a more sustainable inter-
vention than existing NTD control strategies [24].
There are some broader non-disease focused plans
within the global plan to combat NTDs. The promotion
of intersectoral approaches under the plan is designed
to enable structural change as part of an integrated
package of multiple interventions. Intersectoral
approaches theoretically consist of joint working across
areas such as education, civil engineering and local gov-
ernment, not just the health sector [25]. Unfortunately,
although there are good examples of where this
approach has worked, it is usually implemented on a
small scale, relying largely on the goodwill of individuals
rather than at broader policy and implementation levels
[26-28]
The gaps
The current strategy is described as a comprehensive
blueprint [19] towards “rescuing the bottom billion from
poverty” [29] and in general, there has been very little
criticism of the strategy and plans of various NTD pro-
grams. Programmatic indicators, such as increased dis-
tribution of drugs to vendors or distributors and
increased coverage of children through schools, suggest
that there is cause for optimism [14,30]. However, there
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are some concerns. A major problem facing the commu-
nity working on controlling neglected tropical diseases is
the lack of communication between the various players–
researchers, policymakers, clinicians, public-private part-
nerships, donors, and patient advocacy groups. This lack
of communication and synchronisation of efforts repre-
sents a significant missed opportunity for a comprehen-
sive and holistic approach to sustainable outcomes.
Specific gaps are discussed below.
At the technical level, there remain questions about
the appropriateness of integrated chemotherapy across
different age groups. There is also limited understanding
of the most appropriate a) time intervals between var-
ious drug administration b) efficient delivery systems; c)
monitoring and evaluation systems; d)mapping of drug
interactions; e) monitoring of compliance; f) develop-
ment and spread of resistance; g) parameters for move-
ment from morbidity control to transmission
containment and then elimination [31]. More urgently,
significant challenges have been identified in attempts to
integrate these vertical programs into often weak, hori-
zontal health systems [32]. Attempts to coordinate
national health priorities with donor reporting require-
ments has resulted in further fragmentation of efforts to
strengthen national health system [16,33,34].
Further concerns have been raised by researchers who
have either collaborated with implementation teams or
worked with communities that have been targeted for
integrated programs for NTD control [35,105]. Many of
the concerns stem from the community responses to
‘top down’ approaches that expose already vulnerable
communities to further subjugation. There is also often
a lack of understanding by programmatic staff, of the
contexts in which these programs are implemented.
There is a further question, given patterns of re-emer-
gence [36-38], about country ownership and sustainabil-
ity once the attention of global health funders is turned
elsewhere.
These issues relate largely to working with commu-
nities and health systems within a real life, uncontrolled
environment and are raised regularly in community
based programs. There have been discussions for
instance on mobile versus community based distribution
of treatments such as Ivermectin [39]. This study high-
lighted the gains in programs that involved community
participation versus top down programs with expecta-
tions of community compliance. The study also empha-
sizes the challenges of working with community health
workers who do not have a formal role in the health
sector. Some of these lessons have informed APOC and
other community directed interventions [40]. Other
community based health programs have identified signif-
icant clashes between community and health service
personnel where there was a clear lack of fit between
community and health service priorities [41]. This has
been particularly the case where there is a perception
that programs originate from foreign countries and may
not be in the best interest of communities [42]. These
issues are often dismissed as quirky community based
phenomena and seldom result in a significant research
agenda. Where there is an associated research program,
it is either focused on evaluation [42,43] or commis-
sioned to explore the ‘bottlenecks’ that hinder what
should otherwise be an efficacious intervention [44].
Consequently, there is no significant interdisciplinary
research effort to explore solutions to NTDs that are
acceptable and appropriate for communities.
There are also some more fundamental gaps that
relate to understanding and addressing the more persis-
tent social, cultural, economic and environmental factors
that sustain vulnerability and high risk to these NTDs
and other diseases of poverty. An understanding of the
contextual factors that affect the neglected people who
suffer from neglected diseases is essential to any inter-
vention. The proposed solutions under the current strat-
egy are public health, population based solutions, as
opposed to individual clinical treatments. Therefore the
strategy needs to consider the individual within their
immediate social, cultural and physical environment, the
structural factors that guide any choices they might
have to control their health - health infrastructure,
health systems, issues of access - which are in turn
influenced by the political, policy and economic envir-
onment within governance structures. These are all in
turn influenced by the social values that prevail within
the society - equity, inclusion, human rights, regulation
etc. Essentially there needs to be more than what cur-
rently is largely a tokenistic or rhetorical attempt to
engage with other disciplines and sectors [12,26,44,45].
This would require an understanding of what different
disciplines could contribute.
Opportunities to address the neglected contexts of NTDs
There has been a tendency, particularly in public health
research, to assume that social science research comes
from a homogenous group of academic disciplines, and
provides a standard set of tools (usually interviews and
focus group discussions) applied and interpreted in a
subjective manner. These tools then provide some infor-
mation to tell us what a handful of people think or feel,
which may or may not have a bearing on a pre-ordained
plan for intervention. For researchers working particu-
larly in disease focused areas, evidence that comes from
social scientists that is not presented in an empirically
based paradigm with which they are familiar, is dis-
missed as unscientific and incapable of making any real
contribution [46]. The lack of understanding portrayed
in this assumption would be akin to an assumption that
Allotey et al. Health Research Policy and Systems 2010, 8:32
http://www.health-policy-systems.com/content/8/1/32
Page 3 of 8
a biomedical scientist would be just as competent in
pathology or genetics as they would be in molecular
biology or general practice. And further to that, an
assumption that there would be similar methods that
are used across all these disciplines.
“Social sciences” represent a collection of academic,
theoretically grounded disciplines that share a broad
interest in human society. The applied areas of various
social science disciplines attempt to translate the theore-
tical traditions into research and evidence for practice.
Anthropology for instance attempts to provide a holistic
account of humans within the context of their cultures.
This could include the systematic exploration of physi-
cal, biological, social, linguistic and historical artefacts
that culminate to provide a picture of the area of inter-
est. In medical anthropology, studies explore aspects of
the culture that relate to health, illness and disease;
from explanatory models of ill health; stigmatisation;
and health practitioners usage and practice through to
reasons for compliance with treatment [47-49]. Simi-
larly, economics provides an understanding of how
wealth is produced, distributed and consumed at the
household level in microeconomics and at a broader
societal or national level in macroeconomics. The
applied area of health economics provides insights into
how to address the critical issues of catastrophic expen-
diture, providing cost effective interventions that are
affordable both for governments and for consumers,
questions of financing of health systems, implications of
providing good quality human resources, and tradeoffs
between equity and efficiency etc. Other applied social
science disciplines with an interest in health are, inter
alia, medical sociology, social policy, political science,
human geography, social epidemiology etc.
The social sciences have provided a robust evidence
base and theoretical understanding for the description
of the lives of neglected people [29,50-54]. Studies in
anthropology and sociology provide insights into cul-
tural perceptions and practices and how these provide
meaning and frame choices for livelihoods, health and
health seeking. TDR, a co-sponsored Special Program
for Research and Training on Tropical Diseases, exe-
cuted by WHO, has provided strong leadership in the
development of research capacity and the evidence base
to foster a better understanding of various social, eco-
nomic and behavioural factors in tropical diseases
[55-57]. There has also been a recent interest in extend-
ing research on the effects of the environment and cli-
mate change [58,59]. TDR among others, has funded
research which demonstrates the effects of stigma and
stigmatization [50,60-66]; and the fluidity with which
gender dynamics support or hinder exposure to disease,
access and ability to seek health care and the sequelae
of disease [67-71]. We understand for instance that
stigmatisation, social isolation and disfigurement are
vulnerabilities that result from social and cultural norms
of what is considered normal and who is an acceptable
member of the community [51,72,73]. We also know
that while there are diseases that can result in stigmati-
sation, stigmatisation can also result in increased expo-
sure to disease and exacerbate the sequelae [74]. The
effects of these social determinants on health are less
directly observable than bacteria in a Petri-dish and
therefore require interventions that are distinctly differ-
ent from a drug or vaccine, operating at a socio-ecologi-
cal rather than simply biological level.
The recent report from the WHO Commission on
Social Determinants of Health (CSDH) also provides
comprehensive data on the inequity in health outcomes
for the poorer members of society [75]. The World
Bank produces regular global monitoring reports on
poverty and its consequences [76]. There is also some
research on the effects of conflict and displacement
[77-79] and the lives of the rural poor and nomadic
people [80,81]. The research provides insights that are
not only descriptive but also analytical in their ability to
identify complex relationships between various factors.
The now extensive body of work in health and develop-
ment economics supports a basic understanding of
household economies in families living in poverty and
has also increased our understanding of poor commu-
nities’ willingness and ability to pay for health related
interventions [82-88].
To say the social sciences have been overlooked in
global public health efforts would be inaccurate
[45,89,103,104] (see also Reidpath and Pokhrel in this
series). The techniques and research approaches devel-
oped through these disciplines have been packaged and
applied to good effect in other areas in public health to
help in the translation of biomedical research into policy
and clinical and public health practice. These applica-
tions include program evaluation, health services
research, health systems research and implementation
research [44,82,90]. Health services research for instance
develops the evidence base for financing, organization,
delivery, evaluation, and outcomes of health services.
Health systems research is defined to include structures,
equipment, supplies, policies, people and processes [82]
p0719. Implementation research is defined as applied
research that aims to develop the critical evidence base
that informs the effective, sustained and embedded
adoption of interventions by health systems and com-
munities. It deals with the knowledge gap between effi-
cacy, effectiveness and current practice to produce the
greatest gains in disease control [44]. There have also
been recent innovations to combine environmental
social determinants with epidemiological screening and
surveillance tools [91].
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The methods used for these applied areas include a
wide suite of quantitative and qualitative research tech-
niques driven by the specific research question and the
particular conceptual framework which best captures
the issue. Rigorously undertaken these all produce evi-
dence in various forms that inform public health chal-
lenges. In spite of the potential that this research has,
and the growing evidence based that is being produced,
it is unclear how well this wealth of data is being
applied and integrated into global health programs such
as those laid out for NTD control [90,92-94].
Conclusion
The intense advocacy that preceded the profile that
NTDs currently enjoy was remarkable and indeed a sys-
tematic analysis of this process would make an impor-
tant contribution to our understanding of advocacy and
the dynamic research-policy-practice nexus in public
health. The NTDs campaign has relentlessly highlighted
the plight of the populations affected by the range of
target diseases. A great deal has been made of stigmati-
zation, disfigurement, persistent poverty, poor maternal
and child health outcomes, poor health and education
of children caused by infectious diseases. The choice of
the word “neglect” is pointed and loaded, forcing us to
reflect on our social obligations. Inherent in this cam-
paign strategy is an appeal for the recognition of human
suffering and the need for social justice [47]. However,
while preventive chemotherapy and active case manage-
ment might demonstrate a reduction in the incidence
and prevalence of specific diseases, they do not; in and
of themselves, alleviate poverty or stigmatization;
improve equity or livelihoods, or change the environ-
mental conditions which present an ongoing risk for the
poor. Notwithstanding the appropriation of these
broader determinants and value laden constructs in the
NTD lobby process, interventions include very little to
address them.
A strategy that responds to the NTDs lobby, morally
and ethically requires intervention addressing the root
causes of suffering and vulnerability. These causes are
not however, confined to infectious diseases. Critically,
the cause-effect relationship is bidirectional - poverty
increases vulnerability and exposure to disease and
affects access to treatment and the outcome of disease.
The futility of the removal of specific diseases without
addressing poverty as well has been raised time and
again. More recently, the message features prominently
on the home page of the WHO/CSDH and reads: “why
treat people without changing what makes them sick”
[95]. At the very least increasing standards of living,
provision of the basic human rights of food/water, shel-
ter, and clothing are definitive interventions towards the
elimination of NTDs. The body of evidence that
supports the need for structural intervention is signifi-
cant [96]. Tackling structural problems is harder
because the interventions required are more complex;
some have suggested too complex to consider [97].
However not intervening at these levels compounds the
futility of current efforts. The re-emergence of diseases
that were supposed to have been eradicated 40 years
ago [36] is a case in point.
The basic concern here is not new and to a significant
degree, revisits the major, largely unresolved debates
that raged almost 40 years ago between proponents and
opponents of Primary Health Care (PHC) [98-100]. The
critical question is this: does one narrowly partition out
individual causes, in this instance one disease causing
pathogen or another, and address them as independent
context free problems amenable to context free solu-
tions? Or alternatively is there a need for a different
approach which attempts to address the multiple causes
of a disease (not just the infectious agent) within the
context in which they occur? The primary health care
debate’s answer to this question was the introduction of
Selective Primary Health Care programs [101]. These
vertical programs were the precursor of the current con-
text-free, pathogen focussed NTDs strategy. Under the
guise of a ‘pro-poor’ strategy and a vaccine against pov-
erty, it remains a medical and technological fix; the
“magical bullet” to combat disease and therefore a social
problem [98].
We obviously do not underestimate the importance of
biomedical technologies to managing NTDs. However it
is also critical that they should not be over-estimated.
Without significant efforts to address health and pov-
erty, along with the myriad marginalising factors in the
social, cultural, economic, political and physical environ-
ments in which affected populations live, there will con-
tinue to be neglected people and neglected contexts.
Vaccines and drugs do not cure neglect or poverty and
are not a sufficient condition (and quite possibly not
even a necessary condition) to “rescue the bottom bil-
lion” from poverty [29].
To obtain the higher objective of improving health
and reducing vulnerabilities, it is important for research-
ers, policy makers and funding agencies to broaden the
perspective on the range of research and the integrated
of interventions that are needed to address neglected
diseases of neglected populations, and to rethink the
nature of evidence to show effectiveness. There is a
need to refocus on the health of neglected populations
[98] - and not merely removing disease.
There are two major areas that need to be considered
for a sustainable impact ‘neglected’ tropical diseases:
1. To extend the persistent, narrow view of health
improvements based on medical interventions and
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technological fixes towards a broader agenda of
health improvements based on dynamic process (of
which medical interventions are but one of the
inputs) that enable individuals to interact optimally
with their environments [98].
2. To enhance the implementation of programs
towards outcomes that address health as an issue
that encompasses more than the absence of disease.
For this there needs to be balanced investment across
areas of health research that enable an outcome that
ensures the health of populations not the reduction of
the incidence of a specific disease. Ultimately sustainable
solutions for neglected populations will not come from
eradication of infections but from the eradication of
poverty [102].
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